Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL673090 | 0.92 | TLR7 (0.60) | TLR7TLR8 | |
| Fumaric Acid SCHEMBL673089 | 0.92 | TLR7 (0.60) | TLR7TLR8 | |
| Maleic Acid SCHEMBL29849281 | 0.92 | TLR7 (0.60) | TLR7TLR8 | |
| SCHEMBL22300849 | 0.91 | TLR7 (0.61) | TLR7TLR8 | |
| SCHEMBL16306624 | 0.91 | TLR7 (0.58) | TLR7TLR8 | |
| SCHEMBL22854078 | 0.90 | TLR7 (0.57) | TLR7TLR8 | |
| SCHEMBL28435028 | 0.90 | TLR7 (0.60) | TLR7TLR8 | |
| SCHEMBL29642043 | 0.90 | TLR7 (0.60) | TLR7TLR8 | |
| SCHEMBL22790539 | 0.89 | TLR7 (0.56) | TLR7TLR8 | |
| SCHEMBL22301797 | 0.88 | TLR7 (0.57) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12201688-B2 | Lipidated immune response modifier compound compositions, formulations, and methods | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2025-01-21 | — | — | US | disclosed |
| US-20240252617-A1 | CORONAVIRUS SPIKE PROTEIN DESIGNS, COMPOSITIONS AND METHODS FOR THEIR USE | DUKE UNIVERSITY | 2024-08-01 | — | — | US | disclosed |
| EP-4291569-A1 | CORONAVIRUS SPIKE PROTEIN DESIGNS, COMPOSITIONS AND METHODS FOR THEIR USE | Duke University (US) | 2023-12-20 | — | — | EP | disclosed |
| US-11744876-B2 | Immunomodulator antibody drug conjugates and uses thereof | SUTRO BIOPHARMA, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11744876-B2 | Immunomodulator antibody drug conjugates and uses thereof | SUTRO BIOPHARMA, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| WO-2023150899-A1 | CONJUGATES OF CHEMOTHERAPY AGENTS AND TISSUE-BINDING SMALL MOLECULES, COMPOSITIONS AND METHODS THEREOF | CANWELL BIOTECH LIMITED (CN) | 2023-08-17 | — | — | WO | disclosed |
| US-20230090437-A1 | LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND COMPOSITIONS, FORMULATIONS, AND METHODS | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2023-03-23 | — | — | US | disclosed |
| EP-3222621-B1 | LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND AND ITS MEDICAL USE | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2023-03-08 | — | — | EP | disclosed |
| US-11524071-B2 | Lipidated immune response modifier compound compositions, formulations, and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2022-12-13 | — | — | US | disclosed |
| WO-2022173940-A1 | CORONAVIRUS SPIKE PROTEIN DESIGNS, COMPOSITIONS AND METHODS FOR THEIR USE | DUKE UNIVERSITY (US) | 2022-08-18 | — | — | WO | disclosed |
| US-9242980-B2 | Lipidated immune response modifier compound compositions, formulations, and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2016-01-26 | — | — | US | disclosed |
| US-20150352218-A1 | HYDRAZINO 1H-IMIDAZOQUINOLIN-4-AMINES AND CONJUGATES MADE THEREFROM | 3M INNOVATIVE PROPERTIES COMPANY | 2015-12-10 | — | — | US | disclosed |
| US-9107958-B2 | Hydrazino 1H-imidazoquinolin-4-amines and conjugates made therefrom | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2015-08-18 | — | — | US | disclosed |
| US-20140286988-A1 | HYDRAZINO 1H-IMIDAZOQUINOLIN-4-AMINES AND CONJUGATES MADE THEREFROM | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140227317-A1 | HETEROBIFUNCTIONAL LINKERS WITH POLYETHYLENE GLYCOL SEGMENTS AND IMMUNE RESPONSE MODIFIER CONJUGATES MADE THEREFROM | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-08-14 | — | — | US | disclosed |
| EP-2718292-A1 | HYDRAZINO 1H-IMIDAZOQUINOLIN-4-AMINES AND CONJUGATES MADE THEREFROM | 3M Innovative Properties Company (US) | 2014-04-16 | — | — | EP | disclosed |
| US-20130230578-A1 | LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND COMPOSITIONS, FORMULATIONS, AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-09-05 | — | — | US | disclosed |
| EP-2606047-A1 | LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND COMPOSITIONS, FORMULATIONS, AND METHODS | 3M Innovative Properties Company (US) | 2013-06-26 | — | — | EP | disclosed |
| WO-2012167081-A1 | HYDRAZINO 1H-IMIDAZOQUINOLIN-4-AMINES AND CONJUGATES MADE THEREFROM | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-12-06 | — | — | WO | disclosed |
| WO-2012024284-A1 | LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND COMPOSITIONS, FORMULATIONS, AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140227317-A1 | HETEROBIFUNCTIONAL LINKERS WITH POLYETHYLENE GLYCOL SEGMENTS AND IMMUNE RESPONSE MODIFIER CONJUGATES MADE THEREFROM | IL2, ICOS, CD40 | TLR7 83/4885TLR8 82/4885 |
| US-20140286988-A1 | HYDRAZINO 1H-IMIDAZOQUINOLIN-4-AMINES AND CONJUGATES MADE THEREFROM | IL15, IL2, HNMT | TLR7 54/4885TLR8 192/4885 |
| US-20130230578-A1 | LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND COMPOSITIONS, FORMULATIONS, AND METHODS | IFNG, MYD88, STING1 | TLR7 56/4885TLR8 101/4885 |
| US-20230090437-A1 | LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND COMPOSITIONS, FORMULATIONS, AND METHODS | IRF3, IFNG, STING1 | TLR7 38/4885TLR8 94/4885 |
| US-11524071-B2 | Lipidated immune response modifier compound compositions, formulations, and methods | IFNG, IRF3, STING1 | TLR7 79/4885TLR8 136/4885 |
| US-20150352218-A1 | HYDRAZINO 1H-IMIDAZOQUINOLIN-4-AMINES AND CONJUGATES MADE THEREFROM | IL15, IL2, HNMT | TLR7 54/4885TLR8 192/4885 |
| US-11744876-B2 | Immunomodulator antibody drug conjugates and uses thereof | FCGR1A, FCGR2A, FCGRT | TLR7 210/4885TLR8 87/4885 |
| US-12201688-B2 | Lipidated immune response modifier compound compositions, formulations, and methods | IRF3, IFNG, STING1 | TLR7 38/4885TLR8 94/4885 |
| US-20240252617-A1 | CORONAVIRUS SPIKE PROTEIN DESIGNS, COMPOSITIONS AND METHODS FOR THEIR USE | SARS1, CD14, ACE2 | TLR7 2176/4885TLR8 2625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.